Evidence map›Paper›PMID 35016204›Full record

ArticleBlood advances2022

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.

Ursula S A Stalmann, Fabio Ticconi, Inge A M Snoeren, Ronghui Li, Hélène F E Gleitz, Glenn S Cowley, Marie E McConkey, Aaron B Wong, Stephani Schmitz, Stijn N R Fuchs and 15 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Mathematical modeling ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 4 countries.

Ursula S A StalmannDepartment of Developmental Biology and.
Fabio TicconiInstitute for Computational Genomics, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Aachen, Germany.ORCID 0000-0001-8905-6657
Inge A M SnoerenDepartment of Developmental Biology and.
Ronghui LiInstitute for Computational Genomics, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Aachen, Germany.
Hélène F E GleitzDepartment of Developmental Biology and.ORCID 0000-0001-6138-8916
Glenn S CowleyBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA.
Marie E McConkeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Aaron B WongDepartment of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-1650-2710
Stephani SchmitzDepartment of Developmental Biology and.ORCID 0000-0003-1188-2750
Stijn N R FuchsDepartment of Developmental Biology and.
Shubhankar SoodGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Nils B LeimkühlerOncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0003-2530-4329
Sergio Martinez-HøyerOncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Bella BanjaninDepartment of Developmental Biology and.
David RootBroad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0001-5122-861X
Tim H BrümmendorfDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation.ORCID 0000-0002-9677-3723
Juliette E PearceDepartment of Cell Biology, Institute for Biomedical Engineering, Faculty of Medicine, and.
Andreas SchuppertJoint Research Center for Computational Biomedicine, RWTH Aachen University, Aachen, Germany.
Eric M J BindelsDepartment of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Marieke A EssersGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Dirk HecklPediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Thomas StiehlInstitute for Computational Biomedicine-Disease Modeling, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; and.ORCID 0000-0001-9686-9197
Ivan G CostaInstitute for Computational Genomics, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, Aachen, Germany.ORCID 0000-0003-2890-8697
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-0197-5451
Rebekka K SchneiderDepartment of Developmental Biology and.
Oncode Institute · NLRWTH Aachen University · DEBroad Institute · USGerman Cancer Research Center · DEInstitute for Biomedical Engineering · CHDana-Farber Cancer Institute · USErasmus MC · NLErasmus MC Cancer Institute · NLHoward Hughes Medical Institute · USMartin Luther University Halle-Wittenberg · DE

Funding

Functional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8M
NHLBI NIH HHS R01 HL082945
6 · The paper itself

Abstract

How genetic haploinsufficiency contributes to the clonal dominance of hematopoietic stem cells (HSCs) in del(5q) myelodysplastic syndrome (MDS) remains unresolved. Using a genetic barcoding strategy, we performed a systematic comparison on genes implicated in the pathogenesis of del(5q) MDS in direct competition with each other and wild-type (WT) cells with single-clone resolution. Csnk1a1 haploinsufficient HSCs expanded (oligo)clonally and outcompeted all other tested genes and combinations. Csnk1a1-/+ multipotent progenitors showed a proproliferative gene signature and HSCs showed a downregulation of inflammatory signaling/immune response. In validation experiments, Csnk1a1-/+ HSCs outperformed their WT counterparts under a chronic inflammation stimulus, also known to be caused by neighboring genes on chromosome 5. We therefore propose a crucial role for Csnk1a1 haploinsufficiency in the selective advantage of 5q-HSCs, implemented by creation of a unique competitive advantage through increased HSC self-renewal and proliferation capacity, as well as increased fitness under inflammatory stress.

Indexed as

Chromosome DeletionMyelodysplastic SyndromesHaploinsufficiencyHematopoietic Stem CellsHumans

Identifiers

PMID35016204
PMCPMC8941465
OpenAlexW4206694698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.